Targeting ERK-MYD88 interaction leads to ERK dysregulation and immunogenic cancer cell death

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• The RAS/MAP kinase pathway, particularly ERK, is vital in cancer development.
• ERK's interaction with MYD88 is essential for RAS-driven cancer cell survival.
• Targeting this interaction offers a potential therapeutic strategy.

Purpose of the Study:

• To investigate the effects of disrupting the ERK-MYD88 interaction.
• To evaluate the efficacy of EI-52, a novel inhibitor of this interaction.

Main Methods:

• Utilized a small-molecule benzimidazole (EI-52) to target the ERK D-recruitment site.
• Assessed the induction of integrated stress response (ISR) and apoptosis.
• Evaluated anti-tumor efficacy in patient-derived tumors and in vivo mouse models.
• Monitored T cell responses.

Main Results:

• EI-52 induced an HRI-mediated ISR, leading to cancer-specific immunogenic apoptosis.
• EI-52 demonstrated anti-tumor efficacy against patient-derived tumors.
• EI-52 promoted an anti-tumor T cell response in vivo.

Conclusions:

• Disrupting the ERK-MYD88 interaction is a viable strategy for cancer therapy.
• EI-52 represents a promising therapeutic candidate for cancer treatment.
• Targeting this interaction may enhance anti-tumor immunity.